Myo-Inositol: The New Challenge in Treatment of Polycystic Ovary with Infertility.

Inas  A. Yahea; Ahmed ] G. Elsayed

doi:10.64516/tf2pxj92

Authors

Inas A. Yahea 1Fculty of medicine, Gynecology and Obstetrics Department, Tobruk University, Libya. Author
Ahmed G. Elsayed Tobruk Medical Center, Pathology Department, Libya. Author

DOI:

https://doi.org/10.64516/tf2pxj92

Keywords:

PCOS, Infertility, Myo-inisitol

Abstract

Introduction: Polycystic ovarian syndrome (PCOS) is the most prevalent endocrine disorder in women of reproductive age, affecting approximately 6–15% of them associated with chronic anovulation. Myo-inisitol is insulin-sensitizing agent ingested with food and actively synthetized in liver and brain. Aim of the work: To study the effect of Myo-inositol and Metformin in treatment of PCOS with infertility in Tobruk-Libya. Methods: The study group included 800 selected cases of PCOS with infertility and insulin resistance, diagnosed and treated in Gynecology and Obstetrics department of Tobruk Medical Center, Libya, from January 2018 to January 2022. Patients then were randomly distributed into two groups; Group 1 (n = 400) in which Myo-inositol 2000 mg daily by taking two tablets (2x500 mg) after breakfast and another tow tablets after dinner and take Metformin 850 mg during lunch. Group 2 (n = 400) in which they take Metformin 850 mg during lunch only. All patients were followed up by ultrasound to see the progress of ovulation. Results: The mean age of the patients at group 1 is 29 years (range, 18–40 years) and at group 2 is 32 years (range, 22–42 years). Mean pre-study serum glucose level is 193 mg/dl in group 1 and 208 mg/dl in group 2. Mean pre- study Insulin level is 284 mIU/L in group 1 and 295 mIU/L in group 2. There are highly significant relationship between treatment with Myo-inisitol and Metformin (Group-1) with serum glucose level, serum insulin level, acne, hirsutism, body weight, menstrual cycle regularity, follicles diameter and pregnancy. Conclusion: Our results shows that use of Myo- inositol and Metformin is a useful treatment of polycystic ovary with infertility with improvement of laboratory, clinical and ovulation with subsequent pregnancy.

References

1. Ehrmann DA: Polycystic ovary syndrome. N Engl J Med. 2005, 352:1223-1236.

2. Franks S: Polycystic ovary syndrome. N Engl J Med. 1995, 333:853-861.

3. Baillargeon JP, Nestler JE: Polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin?. J Clin Endocrinol Metab. 2006, 91:22-24.

4. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G: Ovulatory and metabolic effects of Dchiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999, 340:1314-1320.

5. Gerli S, Papaleo E, Ferrari A, Di Renzo GC: Randomized double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007, 11:347-354.

6. Gerli S, Mignosa M, Di Renzo GC: Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci. 2003, 7:151-159.

7. Ng EH, Wat NM, Ho PC: Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double blinded placebo-controlled trial. Hum Reprod. 2001, 16:1625-1631.

8. Legro RS, Barnhart HX, Schlaff WD, et al.: Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007, 356:551-566.

9. Bevilacqua, A.; Bizzarri, M. Inositols in Insulin Signaling and Glucose Metabolism. Int. J. Endocrinol. 2018, 2018, 1–8.

10. Halsted, C.H. Handbook of Vitamins: Nutritional, Biochemical, and Clinical Aspects. J. Nutr. 1987, 117, 397.

11. Beemster, P.; Groenen, P.; Steegers-Theunissen, R. Involvement of Inositol in Reproduction. Nutr. Rev. 2002, 60, 80–87.

12. Chukwuma, C.I.; Ibrahim, M.A.; Islam, S. Myo-inositol inhibits intestinal glucose

absorption and promotes muscle glucose uptake: A dual approach study. J. Physiol.

Biochem. 2016, 72, 791–801.

13. Cammarata, P.R.; Chen, H.Q.; Yang, J.; Yorio, T. Modulation of myo-[3H] inositol

uptake by glucose and sorbitol in cultured bovine lens epithelial cells. II. Characterization of high- and low-affinity myo-inositol transport sites. Investig. Ophthalmol. Vis. Sci. 1992, 33, 3572–3580.

14. Sivalingam VN, Myers J, Nicholas S, Balen AH, Crosbie EJ. Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indications. Hum Reprod Update. 2014;20:853-868.

15. Palomba S, Falbo A, Zullo F, Orio F Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev. 2009;30:1-50.

16. Azziz, R.; Carmina, E.; Dewailly, D.; Diamanti-Kardarakis, E.; Escobar-Morreale, H.F.; Futterweit, W.; Janssen, O.E.; Legro, R.S.; Norman, R.J.; Taylor, A.E.; et al. Positions statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guideline. J. Clin. Endocrinol. Metab. 2006, 91, 4237–4245.

17. Teede, H.J.; Deeks, A.; Moran, L.J. Polycystic ovary syndrome: A complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010, 8, 41.

18.Aversa,A.;LaVignera,S.;Rago,R.;Gambineri,A.;Nappi,R.E.;Calogero,A.E.;Ferlin, A. Fundamental Concepts and Novel Aspects of Polycystic Ovarian Syndrome: Expert Consensus Resolutions. Front. Endocrinol. 2020, 11, 516.

19. Usadi, R.S.; Legro, R.S. Reproductive impact of polycystic ovary syndrome. Curr. Opin. Endocrinol. Diabetes Obes. 2012, 19, 505–511.

20. Moran, L.; Gibson-Helm, M.; Teede, H.; Deeks, A. Polycystic ovary syndrome: A biopsychosocial understanding in young women to improveknowledge and treatment options. J. Psychosom. Obstet. Gynecol. 2010, 31, 24–31.

21. Deeks, A.; Gibson-Helm, M.; Teede, H. Is having polycystic ovary syndrome (PCOS) a predictor of poor psychological function including depression and anxiety. Hum. Reprod. 2011, 26, 1399–1407.

22. Teede, H.J.; Misso, M.L.; Costello, M.F.; Dokras, A.; Laven, J.; Moran, L.; Piltonen, T.; Norman, R.J. International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil. Steril. 2018, 110, 364–379.

23. Iuorno, M.J.; Nestler, J.E. Insulin-lowering drugs in polycystic ovary syndrome. Obstet. Gynecol. Clin. North. Am. 2001, 28, 153–164.

24. Donà, G.; Sabbadin, C.; Fiore, C.; Bragadin, M.; Giorgino, F.L.; Ragazzi, E.; Clari, G.; Bordin, L.; Armanini, D. Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome. Eur. J. Endocrinol. 2012, 166, 703–710.

25. Genazzani, A.D.; Lanzoni, C.; Ricchieri, F.; Jasonni, V.M. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweith patients with polycystic ovary syndrome. Gynecol. Endocrinol. 2008, 24, 139–144.

26. Unfer, V.; Facchinetti, F.; Orrù, B.; Giordani, B.; Nestler, J. Myo-inositol effects in women with PCOS: A meta-analysis of randomized controlled trials. Endocr. Connect. 2017, 6, 647–658.

27. Shokrpour, M.; Foroozanfard, F.; Ebrahimi, F.A.; Vahedpoor, Z.; Aghadavod, E.; Ghaderi, A.; Asemi, Z. Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: A randomized controlled clinical trial. Gynecol. Endocrinol. 2019, 35, 406–411.

28. Agrawal, A.; Mahey, R.; Kachhawa, G.; Khadgawat, R.; Vanamail, P.; Kriplani, A. Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: Randomized controlled trial. Gynecol. Endocrinol. 2019, 35, 511–514.

29. Minozzi, M.; D’Andrea, G.; Unfer, V. Treatment of hirsutism with myo-inositol: A prospective clinical study. Reprod. Biomed. 2008, 17, 579–582.

30. Regidor, P.-A.; Schindler, A.E.; Lesoine, B.; Druckman, R. Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature. Horm. Mol. Biol. Clin. Investig. 2018, 34.

31. Papaleo, E.; Unfer, V.; Baillargeon, J.-P.; Fusi, F.; Occhi, F.; De Santis, L. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil. Steril. 2009, 91, 1750–1754.

32. Zacchè, M.M.; Caputo, L.; Filippis, S.; Zacchè, G.; Dindelli, M.; Ferrari, A. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol. Endocrinol. 2009, 25, 508–513.

33. Ciotta, L.; Iozza, I.; Rubbino, G.; Iemmola, A.; Lizzio, I.; Teodoro, M.C.; Palumbo, M. Treatment of hyperandrogenism by myo-inositol. In Proceedings of the 14th World Congress of Gynecological Endocrinology, Firenze, Italy, 4–7 March 2010.

34. Unfer,V.; DiNicola, S.; Laganà, A.S.; Bizzarri, M. Altered Ovarian Inositol Ratios MayAccount for Pathological Steroidogenesis in PCOS. Int. J. Mol. Sci. 2020, 21, 7157.

35. Di Berardino, O.M.; Monteleone, P.; Valentino,V.; Ruggiero, M.; Papini, F.; Cela,V.; Artini, P.G.; Genazzani, A.R. Myo-inositol administration in PCOS patients after IVF. In Proceedings of the 14th World Congress of Gynecological Endocrinology, Firenze, Italy, 4–7 March 2010.

36. Kamenov, Z.; Kolarov, G.; Gateva, A.; Carlomagno, G.; Genazzani, A.D. Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. Gynecol. Endocrinol. 2015, 31, 131–135.

37. Morgante, G.; Orvieto, R.; Di Sabatino, A.; Musacchio, M.C.; De Leo, V. The role of inositol supplementation in patients with polycystic ovary syndrome, with insulin resistance, undergoing the low-dose gonadotropin ovulation induction regimen. Fertil. Steril. 2011, 95, 2642–2644.

38. Papaleo, E.; Unfer, V.; Baillargeon, J.-P.; De Santis, L.; Fusi, F.; Brigante, C.; Marelli, G.; Cino, I.; Redaelli, A.; Ferrari, A. Myo-inositol in patients with polycystic ovary syndrome: A novel method for ovulation induction. Gynecol. Endocrinol. 2007, 23, 700– 703.

39. LeDonne,M.;Metro,D.;Alibrandi,A.;Papa,M.;Benvenga,S.Effectsofthreetreatment modalities (diet, myoinositol or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome. Eur. Rev. Med. Pharmacol. Sci. 2019, 23, 2293–2301.

40. Raffone, E.; Rizzo, P.; Benedetto, V. Insulin sensitizer agents alone and in co-treatment with rFSH for ovulation induction in PCOS women. Gynecol. Endocrinol. 2010, 26, 275– 280.

41. Le Donne, M.; Alibrandi, A.; Giarrusso, R.; Monaco, I.L.; Muraca, U. Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: Effects on body composition. Minerva Ginecol. 2012, 64, 23.